Patents by Inventor Hiroto Hara
Hiroto Hara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11935282Abstract: A server of a crop growth stage determination system includes a processor. The processor inputs first images obtained by image capturing crops in a manner such that crop shapes are extractable. The Processor inputs growth stages each indicating a level of physiological growth of the crops for each of the first images. The processor constructs a learned model by performing deep learning to associate images of the crops and growth stages of the crops based on the input first images and the input growth stage. The processor inputs a second image obtained by image capturing crops a growth stage of which is unknown, in a manner such that crop-shapes are extractable. The processor determines the growth stage for the input second image based on the learned model. The processor outputs the determined growth stage.Type: GrantFiled: February 26, 2021Date of Patent: March 19, 2024Assignees: NTT DATA CCS CORPORATIONInventors: Norio Iwasawa, Aritoshi Mio, Seiichi Hara, Hiroto Shimojo, Hiroshi Takemoto
-
Patent number: 11103574Abstract: In this invention, a non-infectious particle has been produced, comprising a pathogen antigen protein caused to be expressed on the surface of a virus particle having at least one species of paramyxovirus envelope protein missing from the particle. This particle has been found to hold within the particle a large amount of antigen protein compared to an infectious particle, and to be capable of eliciting a host immune response with extremely high efficiency. The non-infectious particle according to the present invention is useful as a vaccine against a pathogenic virus, or the like.Type: GrantFiled: November 17, 2017Date of Patent: August 31, 2021Assignees: Japan, as represented by the Director-General of National Institute of Infectious Disease, ID Pharma Co., Ltd.Inventors: Tetsuro Matano, Makoto Inoue, Hiroto Hara, Tsugumine Shu
-
Patent number: 10792357Abstract: The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.Type: GrantFiled: March 4, 2019Date of Patent: October 6, 2020Assignee: INTERNATIONAL AIDS VACCINE INITIATIVEInventors: Christopher L. Parks, Maoli Yuan, Xinsheng Zhang, Aaron Wilson, Angela Grazia Lombardo, Eddy Sayeed, Josephine Helena Cox, Takashi Hironaka, Makoto Inoue, Hiroto Hara
-
Publication number: 20200283797Abstract: An objective of the present invention is to provide an improved negative-strand RNA viral vector and a use thereof, the negative-strand RNA viral vector exhibiting transient high expression of genes loaded in the vector and enabling the rapid removal of the vector after said expression. It was discovered that by adding a micro-RNA target sequence to the NP, P, or L gene of a negative-strand RNA viral vector, it is possible to control the expression of the vector depending on the micro-RNA expressed by the introduction cell. In particular, when a micro-RNA target sequence was added to the NP or P gene, the expression of the vector decreased depending on the micro-RNA, and the removal of the vector was promoted, while the effect was reversed when a micro-RNA target sequence was added to the L gene. The vector can be applied in cell therapy and regenerative medicine and can be used as a therapeutic vector that targets cancer.Type: ApplicationFiled: November 4, 2016Publication date: September 10, 2020Applicant: ID Pharma Co., Ltd.Inventors: Koichi SAEKI, Kohji KUSANO, Hiroto HARA, Makoto INOUE, Jitsutaro KAWAGUCHI
-
Publication number: 20200155669Abstract: In this invention, a non-infectious particle has been produced, comprising a pathogen antigen protein caused to be expressed on the surface of a virus particle having at least one species of paramyxovirus envelope protein missing from the particle. This particle has been found to hold within the particle a large amount of antigen protein compared to an infectious particle, and to be capable of eliciting a host immune response with extremely high efficiency. The non-infectious particle according to the present invention is useful as a vaccine against a pathogenic virus, or the like.Type: ApplicationFiled: November 17, 2017Publication date: May 21, 2020Inventors: Tetsuro MATANO, Makoto INOUE, Hiroto HARA, Tsugumine SHU
-
Publication number: 20190201522Abstract: The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.Type: ApplicationFiled: March 4, 2019Publication date: July 4, 2019Inventors: Christopher L. Parks, Maoli Yuan, Xinsheng Zhang, Aaron Wilson, Angela Grazia Lombardo, Eddy Sayeed, Josephine Helena Cox, Takashi Hironaka, Makoto Inoue, Hiroto Hara
-
Publication number: 20190201455Abstract: An object of the present invention is to provide a safe and easy-to-prep cell product for prevention and/or treatment of organ fibrosis such as liver fibrosis. Provided is a cell product for prevention and/or treatment of organ fibrosis such as liver fibrosis, the cell product comprising a SSEA-3-positive pluripotent stem cell (Muse cell) derived from mesenchymal tissue in a living body or a cultured mesenchymal cell.Type: ApplicationFiled: June 30, 2017Publication date: July 4, 2019Applicants: TOHOKU UNIVERSITY, LIFE SCIENCE INSTITUTE, INC.Inventors: Mari DEZAWA, Michiaki UNNO, Toshihiro YAMAMOTO, Yasuhiro SHINDO, Hiroto HARA, Naoya MASUTOMI
-
Patent number: 10220087Abstract: The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.Type: GrantFiled: April 27, 2017Date of Patent: March 5, 2019Assignee: INTERNATIONAL AIDS VACCINE INITIATIVEInventors: Christopher L. Parks, Maoli Yuan, Xinsheng Zhang, Aaron Wilson, Angela Grazia Lombardo, Eddy Sayeed, Josephine Helena Cox, Takashi Hironaka, Makoto Inoue, Hiroto Hara
-
Publication number: 20170258890Abstract: The present invention relates to genetically stable replication competent Sendai virus vector(s) containing optimized HIV genes, methods for making the same and cell substrates qualified for vaccine production which may comprise genetically stable replication competent Sendai virus vector(s) containing optimized HIV genes.Type: ApplicationFiled: April 27, 2017Publication date: September 14, 2017Inventors: John Coleman, Josephine Helena Cox, Arban Domi, Hiroto Hara, Takashi Hironaka, Makoto Inoue, Dagna Skoog Laufer, Angela Grazia Lombardo, Christopher L. Parks, Eddy Sayeed, Maoli Yuan, Xinsheng Zhang
-
Publication number: 20170258891Abstract: The present invention relates to a vector(s) containing and expressing an optimized HIV EnvF gene, methods for making the same and cell substrates qualified for vaccine production which may comprise vector(s) containing optimized HIV genes.Type: ApplicationFiled: April 27, 2017Publication date: September 14, 2017Inventors: Christopher L. Parks, Maoli Yuan, Xinsheng Zhang, Aaron Wilson, Angela Grazia Lombardo, Eddy Sayeed, Josephine Helena Cox, Takashi Hironaka, Makoto Inoue, Hiroto Hara
-
Publication number: 20110162093Abstract: [Problems to be Solved] The present invention provides methods for producing antibodies and antibody-producing cells. [Means for Solving the Problems] The present invention provides methods for producing antibodies or antibody-producing cells, such methods including the steps of inoculating non-human animals with minus-strand RNA viral vectors carrying nucleic acids which encode foreign polypeptides to be used as antigens, nucleic acids producing the viral vectors, cells into which the vectors or the nucleic acids producing the vectors have been introduced, or lysates of the cells; and collecting the antibodies or antibody-producing cells from the animals. The antibody production can be induced efficiently by the immune activating effect of the minus-strand RNA viral vectors and a high expression of the antigen polypeptides. The antibodies produced by the methods of the present invention can be used in research and development and in the clinical field.Type: ApplicationFiled: June 13, 2006Publication date: June 30, 2011Inventors: Yasuji Ueda, Hiroto Hara, Tsugumine Shu, Mamoru Hasegawa
-
Publication number: 20090246170Abstract: The present invention provides novel therapeutic methods and agents for treating Alzheimer's disease. Specifically, the present invention relates to anti-inflammatory cytokines, anti-inflammatory cytokine genes, negative-strand RNA viral vectors carrying an anti-inflammatory cytokine gene, which are used for treating Alzheimer's disease or developing therapeutic agents for Alzheimer's disease. The present invention also provides pharmaceutical compositions for treating or preventing Alzheimer's disease, which comprise the cytokines or vectors. The present invention further provides methods for treating Alzheimer's disease, which comprise the step of administering an anti-inflammatory cytokine, or a vector such as a negative-strand RNA viral vector carrying an anti-inflammatory cytokine gene. The present invention enables novel gene therapies for Alzheimer's disease.Type: ApplicationFiled: May 31, 2007Publication date: October 1, 2009Applicant: DNAVEC CorporationInventors: Makoto Inoue, Yumiko Tokusumi, Hitoshi Iwasaki, Hiroto Hara, Toshiaki Tabata, Mamoru Hasegawa
-
Publication number: 20050250718Abstract: The present invention provides pharmaceutical- or gene-carrier compositions with reduced hemagglutinating activity. By attaching a compound to a minus-strand RNA virus envelope protein having hemagglutinating activity, a pharmaceutical- or gene-carrier composition with lower hemagglutinating activity than a composition to which the compound has not been attached can be successfully constructed. For example, an embodiment of the present invention provides a viral vector whose erythrocyte agglutination activity and hemolytic activity are significantly lowered, and whose stability in blood is remarkably elevated. The pharmaceutical- or gene-carrier compositions provided in this invention can be preferably used for transferring pharmaceuticals or genes in vivo.Type: ApplicationFiled: April 30, 2003Publication date: November 10, 2005Applicant: DNAVEC Research Inc.Inventors: Hiroyuki Sakakibara, Hiroto Hara, Yasuji Ueda, Mamoru Hasegawa, Jun You
-
Patent number: 5789448Abstract: Disclosed is a benzoylethylene derivative represented by the following formula (I) or a salt thereof. ##STR1## R.sup.1 to R.sup.5 : a hydrogen atom, --OR.sup.9 (R.sup.9 : a hydrogen atom, a C.sub.1 -C.sub.5 alkyl group, etc.), etc.,R.sup.6 : a hydrogen atom, a C.sub.1 -C.sub.5 alkyl group, etc.,R.sup.7 : a hydrogen atom, a cyano group, a C.sub.1 -C.sub.5 alkyl group, --SO.sub.q R.sup.15 (q: 0, 1, 2, R.sup.15 : a thienyl group, a phenyl group, etc.) etc.,R.sup.8 : a cyano group, --CR.sup.22 R.sup.23 X (R.sup.22, R.sup.23 : a hydrogen atom, a C.sub.1 -C.sub.5 alkyl group, etc., X: --NR.sup.24 R.sup.25 (R.sup.24, R.sup.25 : a C.sub.1 -C.sub.5 alkyl group, etc., an alkylene group by combining, etc.)), etc.The benzoylethylene derivative of the present invention has potent tyrosine kinase inhibiting activity and cancer cell growth inhibiting activity. The tyrosine kinase inhibitor of the present invention is useful as a carcinostatic agent.Type: GrantFiled: June 25, 1996Date of Patent: August 4, 1998Assignee: Mitsubishi Chemical CorporationInventors: Yasunori Kitano, Haruki Inokawa, Hisao Takayanagi, Tamaki Yano, Hiroe Umeki, Hiroto Hara
-
Patent number: 5618829Abstract: A pharmaceutical composition which comprises a pharmaceutically effective amount of a compound of the formula ##STR1## wherein R.sup.1 represents a hydrogen atom,R.sup.2 represents --(CH.sub.2).sub.m -Awherein m is an integer of 0 to 3, andA represents pyridyl which is unsubstituted or is substituted by C.sub.1 -C.sub.3 alkyl said alkyl being unsubstituted or substituted by phenyl, and R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 each independently represent a hydrogen atom, a halogen atom, C.sub.1 -C.sub.5 alkyl which is unsubstituted or is substituted with a halogen atom or --OR.sup.13 wherein R.sup.13 represents a hydrogen atom or C.sub.1 -C.sub.5 alkyl which is unsubstituted or is substituted with a halogen atom or phenyl, or when their adjacent substituents are taken together, they represent C.sub.1 -C.sub.3 oxyalkylene having one or two oxygen atoms;or a pharmaceutically acceptable salt thereof, anda pharmaceutically acceptable carrier therefor.Type: GrantFiled: January 25, 1994Date of Patent: April 8, 1997Assignee: Mitsubishi Chemical CorporationInventors: Hisao Takayanagi, Yasunori Kitano, Tamaki Yano, Hiroe Umeki, Hiroto Hara
-
Patent number: 5514711Abstract: Styrene derivatives of the following general formula (I): ##STR1## or pharmaceutically acceptable salts thereof. A pharmaceutical composition useful as anticancer agent, which comprises the above compound as an essential component, is also provided.Type: GrantFiled: January 5, 1995Date of Patent: May 7, 1996Assignee: Mitsubishi Chemical CorporationInventors: Yasunori Kitano, Hisao Takayanagi, Koichi Sugawara, Hiroto Hara, Hideo Nakamura, Toshiko Oshino
-
Patent number: 5032614Abstract: A method of suppressing vasoconstriction in a warm-blooded animal which comprises administering to said warm-blooded animal an effective amount of a serotonin antagonist compound of the formula (I): ##STR1## wherein: R.sup.1 is hydrogen, halo, C.sub.1 -C.sub.5 alkoxy or C.sub.2 -C.sub.6 dialkyl amino;R.sup.2 is hydrogen, halo or C.sub.1 -C.sub.5 alkoxy;R.sup.3 is hydrogen, hydroxy, --O--(CH.sub.2).sub.n --COOH or --O--CO--(CH.sub.2).sub.l --COOH, wherein n is an integer of 1-5, and l is an integer of 1-3;R.sup.4 is ##STR2## wherein R.sup.5 and R.sup.6 are each independently hydrogen or C.sub.1 -C.sub.8 alkyl, and A is C.sub.3 -C.sub.5 alkylene or C.sub.3 -C.sub.5 alkylene substituted with carboxy; andm is an integer of 0-5,or a pharmaceutically acceptable salt thereof. The use of the compound (I) for the preparation of a pharmaceutical formulation useful as a serotonin antagonist is also provided.Type: GrantFiled: May 18, 1990Date of Patent: July 16, 1991Assignee: Mitsubishi Kasei CorporationInventors: Masanori Osakabe, Hiroto Hara, Yoshikuni Tamao, Ryoji Kikumoto
-
Patent number: 4599419Abstract: (3-Aminopropoxy)bibenzyl derivatives are prepared and found useful as pharmaceutical agents, particularly as inhibitors of platelet aggregation.Type: GrantFiled: July 9, 1984Date of Patent: July 8, 1986Assignee: Mitsubishi Chemical Industries, Inc.Inventors: Ryoji Kikumoto, Harukazu Fukami, Hiroto Hara, Kunihiro Ninomiya, Mamoru Sugano
-
Patent number: 4485258Abstract: (3-Aminopropoxy)bibenzyl derivatives are prepared and found useful as pharmaceutical agents, particularly as inhibitors of platelet aggregation.Type: GrantFiled: July 29, 1982Date of Patent: November 27, 1984Assignee: Mitsubishi Chemical Industries LimitedInventors: Ryoji Kikumoto, Harukazu Fukami, Hiroto Hara, Kunihiro Ninomiya, Mamoru Sugano
-
Patent number: 4339452Abstract: Caroverine fumarate has an inhibitory effect on platelet aggregation, and exhibits the beneficial effect of increasing coronary blood flow, especially in coronary arteries, and thus is specifically suitable in applications for ischemic heart diseases.Type: GrantFiled: December 19, 1980Date of Patent: July 13, 1982Assignee: Medichemie AGInventors: Hiroto Hara, Akihiro Narimatsu